Inter Parfums buys Lanvin brands
This article was originally published in The Rose Sheet
Executive Summary
Fragrance firm's 72%-owned Paris subsidiary, Inter Parfums SA, has acquired the worldwide rights to Lanvin brand names and international trademarks listed under Class 3 - those associated with soaps, perfumery, essential oils, cosmetics and hair lotions - for roughly $29.7 mil. in cash, according to an Aug. 1 release. The two companies' licensing contract signed in June 2004 has been terminated (1"The Rose Sheet" June 7, 2004, In Brief). Under the new agreement, "Inter Parfums will also pay to Lanvin a sales-based fee for technical and creative assistance in new product development to be rendered by Lanvin in connection with the use of the Lanvin trademark through June 30, 2019." Lanvin has the right to repurchase the brands and trademarks in 2025. "Lanvin has quickly become the second-largest brand in our prestige fragrance portfolio," Inter Parfums Chair and CEO Jean Madar notes. "Our decision to buy Lanvin Perfumes is indicative of our long-term commitment to growing the Lanvin fragrance business." Lanvin brands include Eclat d'Arpège, Rumeur and Paul Smith...
You may also be interested in...
Inter Parfums/Lanvin deal
Inter Parfums' Paris-based subsidiary, Inter Parfums S.A., and Lanvin are negotiating a "long-term worldwide license agreement for the creation, development and distribution of fragrance lines under the Lanvin brand name," fragrance company announces June 3. Provisions of the deal would include "an upfront license fee, advertising expenditures and royalty payments" as well as the purchase of existing inventory, firm notes. Proposed transaction is contingent upon a formal agreement between the parties. Lanvin fragrance sales reached $33 mil. in 2003, Inter Parfums says. Planned agreement follows announcement by the French fashion company that it would license its fragrance business and focus on its core ready-to-wear collection due to a difficult economic situation (1"The Rose Sheet" April 12, 2004, In Brief)...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.